China Shineway Pharmaceutical (2877.HK) - Uncertainties Cloud the Outlook
233 Views22 Feb 2022 08:58
The strong performance recovery based on 2021H1 reports is a good signal, but how long the positive momentum would last is not sure because the VBP scope has expanded on TCM. So we are conservative.
SUMMARY
(Sign Up to Access)Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
- Unlock all research summaries
- Follow top, independent analysts
- Receive personalised alerts and emails
- Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 5-minute read)
Discussions
(Paid Plans Only)
Top 5%
Xinyao (Criss) Wang
HK/China Healthcare Analyst (ex-Fosun Pharma)
- China Shineway Pharmaceutical (2877HK)-Shineway Is Undervalued, but Downside Risk Is Hard to Control27 Sep 2022
- Pre-IPO Shanghai Pulse Medical Technology - The Industry, the Business and the Concerns19 Aug 2022
- Consun Pharmaceutical (1681HK)- High-Priced Acquisition & Good Performance Show Big Upside Potential16 Aug 2022
- China Shineway Pharmaceutical (2877.HK) - Uncertainties Cloud the Outlook22 Feb 2022
- Presentation for Webinar: China Healthcare - Outlook and Opportunities in 202217 Feb 2022
- The Concerns and Outlook About the Recent Rally in Traditional Chinese Medicine (TCM) Sector06 Jan 2022
- China Healthcare Weekly (Dec.10) - Last Monday's Plunge, New Policy of Gene Therapy, TCM Injections12 Dec 2021
x